Skip to main content
OpenTrials
Completed

NCT Number: NCT03216577

Outcomes of Purpura FULminans in Adults - The hOPeFUL Study

Purpura fulminans (PF) is a rare life-threatening infectious disease characterized by the association of a sudden and extensive purpura together with acute circulatory failure. The mortality of PF has been reported to be as high as 50% in previous adult series. Additionally, patients surviving to the early phase of PF are exposed to a high risk of limb amputation. The hOPeFUL study aims at assessing the short and long term outcomes of adult patients admitted in the intensive care unit for a purpura fulminans.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Aulnay sous Bois Hospital, Aulnay-sous-Bois, France

Loading trial locations.

About this study

Purpura fulminans (PF) is a rare life-threatening infectious disease characterized by the association of a sudden and extensive purpura together with acute circulatory failure. Neisseria meningitidis and Streptococcus pneumoniae are the most frequently involved microorganisms but other species (e.g., Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae…) have also been reported. Despite prompt antibiotics administration and intensive care management, the mortality of PF has been reported to be as high as 50% in previous adult series. Additionally, patients surviving to the early phase of PF are exposed to a high risk of serious sequelae related to extensive skin necrosis and acral symmetrical gangrene, which typically requires limb amputations, a potential source of severe handicap in these previously young and healthy patients. Although the clinical features and outcomes of PF have been well studied in the pediatric setting, the amount of available data for adult PF are scarce, often outdated and mainly limited to patients with meningococcal infections. The current study aims at assessing the short and long-term outcomes of adult patients admitted in the intensive care unit for a purpura fulminans. A large multicenter retrospective cohort will be built in order to assess hospital outcomes (i.e., mortality and amputations). Long-term outcomes, including health-related quality variables, will be prospectively assessed among survivors and compared to septic controls (i.e., patients having septic shock non-related to purpura fulminans).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients admitted in the intensive care unit between 2010 and 2016 for an infectious purpura fulminans and discharged alive

Exclusion criteria

  • Age < 18 years
  • Non infectious purpura
  • Infective endocarditis

Treatment and study plan

Phone interview measuring health-related quality of life variables

Other

A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.

Primary outcomes

  1. Hospital mortality

    Time frame: day 60

    factors associated with hospital mortality (and rate of amputation in the hospital) will be identified using a polytomous logistic regression model

  2. Rate of amputation in the hospital;

    Time frame: day 60

    factors associated with rate of amputation in the hospital (and hospital mortality) will be identified using a polytomous logistic regression model

  3. Long-term outcome measure: Physical dimension scale of the SF-36 questionnaire

    Time frame: Within 6 years of hospital discharge

    This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans

Secondary outcomes

  1. Mental component score of the SF-36 score

    Time frame: Within 6 years of hospital discharge

    This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans

  2. Activity of daily living (ADL score)

    Time frame: Within 6 years of hospital discharge

    This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans

  3. Hospital anxiety and depression scale

    Time frame: Within 6 years of hospital discharge

    This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans

  4. Impact of Event Scale

    Time frame: Within 6 years of hospital discharge

    This variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans

  5. Physical dimension scale of the SF-36 questionnaire

    Time frame: Within 6 years of hospital discharge

    This variable will be compared between patients with purpura fulminans who were and those who were not amputated

  6. Mental component score of the SF-36 score

    Time frame: Within 6 years of hospital discharge

    This variable will be compared between patients with purpura fulminans who were and those who were not amputated

Sponsors and collaborators

Lead sponsor

Henri Mondor University Hospital

Other

Collaborators

  • Fondation de France

Registry information

Official study title

Short and Long-term Outcomes of Purpura Fulminans in Adults

Acronym: hOPeFUL

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jul 13, 2017
Registry last updated
Mar 9, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.